NCT06698042: An ongoing trial by Merck Sharp & Dohme LLC
This trial is ongoing. It must report results 1 year from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06698042 |
|---|---|
| Title | A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS 50% or Greater |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 21, 2024 |
| Completion date | March 16, 2026 |
| Required reporting date | March 16, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Feb. 27, 2026 |
| Days late | None |